Overview

Dynepo Long-Term Safety Study

Status:
Terminated
Trial end date:
2008-07-31
Target enrollment:
Participant gender:
Summary
To assess the incidence rate of Treatment Emergent Adverse Events (TEAEs) over 2 years in patients treated with Dynepo.
Phase:
Phase 4
Details
Lead Sponsor:
Shire
Treatments:
Epoetin Alfa